Phase 2 Clinical Trials

Mid-stage Phase 2 clinical trial results showing efficacy and safety data.

100 UpcomingView Full Calendar

April 202649

Today

MRNAPhase 2$42.1B

mRNA-1405 Phase 2 Results Expected

mRNA-1405• Norovirus Acute Gastroenteritis1,285

Apr 14Estimated

CT.gov

00%

Today

INCYPhase 2$9.9B

epacadostat Phase 2 Results Expected

Epacadostat• Lung Cancer206

Apr 14Estimated

CT.gov

00%

Today

INCYPhase 2$9.9B

retifanlimab Phase 2 Results Expected

Retifanlimab• Metastatic Merkel Cell Carcinoma206

Apr 14Estimated

CT.gov

00%

Today

INCYPhase 2$9.9B

INCAGN02385 Phase 2 Results Expected

INCAGN02385• Endometrial Cancer206

Apr 14Estimated

CT.gov

00%

Today

INCYPhase 2$9.9B

INCAGN02390 Phase 2 Results Expected

INCAGN02390• Melanoma206

Apr 14Estimated

CT.gov

00%

Today

INCYPhase 2$9.9B

pemigatinib Phase 2 Results Expected

Pemigatinib• Non-Small Cell Lung Cancer (NSCLC)206

Apr 14Estimated

CT.gov

00%

Tomorrow

JNGHFPhase 2

HRS-6768 Phase 2 Results Expected

HRS-6768• Advanced Solid Tumors84

Apr 15Estimated

CT.gov

00%

Tomorrow

KPTIPhase 2$37M

Ruxolitinib Phase 2 Results Expected

Ruxolitinib• Myelofibrosis118

Apr 15Estimated

CT.gov

00%

Tomorrow

GILDPhase 2$60.0B

Tilpisertib Fosmecarbil Phase 2 Results Expected

Tilpisertib Fosmecarbil• Ulcerative Colitis176

Apr 15Estimated

CT.gov

00%

Tomorrow

ORKAPhase 2$1.7B

ORKA-001 Induction Dose Phase 2 Results Expected

ORKA-001 Induction Dose• Plaque Psoriasis80

Apr 15Estimated

CT.gov

00%

Tomorrow

AAPGPhase 2$2.5B

Toripalimab Phase 2 Results Expected

Toripalimab• Liposarcoma95

Apr 15Estimated

CT.gov

00%

Tomorrow

LLYPhase 2$769.8B

Bimagrumab Phase 2 Results Expected

Bimagrumab• Obesity240

Apr 15Estimated

CT.gov

00%

Tomorrow

AAPGPhase 2$2.5B

APG-2575 Phase 2 Results Expected

APG-2575• T-Prolymphocytic Leukemia40

Apr 15Estimated

CT.gov

00%

Tomorrow

LIFEPhase 2$803M

efzofitimod 450 mg Phase 2 Results Expected

efzofitimod 450 mg• Interstitial Lung Disease25

Apr 15Estimated

CT.gov

00%

Tomorrow

VMARPhase 2$3M

Atropine Phase 2 Results Expected

Atropine• Myopia, Progressive144

Apr 15Estimated

CT.gov

00%

Tomorrow

KPTIPhase 2$37M

Selinexor 40 mg Phase 2 Results Expected

Selinexor 100 mg• Non-Small Cell Lung Carcinoma (NSCLC)118

Apr 15Estimated

CT.gov

00%

Tomorrow

VTGNPhase 2$81M

Fasedienol Nasal Spray - Fasedienol Nasal Spray Phase 2 Results Expected

Fasedienol Nasal Spray - Fasedienol Nasal Spray• Social Anxiety Disorder60

Apr 15Estimated

CT.gov

00%

Tomorrow

ODYYPhase 2$2M

OD-07656 Phase 2 Results Expected

OD-07656• Ulcerative Colitis (UC)57

Apr 15Estimated

CT.gov

00%

Tomorrow

KYTXPhase 2$65M

Standard lymphodepletion regimen Phase 2 Results Expected

Standard lymphodepletion regimen• Lupus Nephritis25

Apr 15Estimated

CT.gov

00%

Tomorrow

GILDPhase 2$60.0B

Placebo Phase 2 Results Expected

Seladelpar 10 mg• Primary Biliary Cholangitis176

Apr 15Estimated

CT.gov

00%

Tomorrow

YMABPhase 2$450M

GM-CSF + Naxitamab Phase 2 Results Expected

GM-CSF + Naxitamab• Neuroblastoma122

Apr 15Estimated

CT.gov

00%

Tomorrow

AAPGPhase 2$2.5B

APG-115 Phase 2 Results Expected

APG-115• AML95

Apr 15Estimated

CT.gov

00%

Tomorrow

KPTIPhase 2$37M

Selinexor 60 mg Phase 2 Results Expected

Selinexor 60 mg• Myelofibrosis118

Apr 15Estimated

CT.gov

00%

Tomorrow

LLYPhase 2$769.8B

LY3549492 Phase 2 Results Expected

LY3549492• Obesity275

Apr 15Estimated

CT.gov

00%

Tomorrow

VMARPhase 2$3M

SHJ002 Phase 2 Results Expected

SHJ002• Corneal Erosion144

Apr 15Estimated

CT.gov

00%

days

SNYPhase 2$115.3B

Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 Phase 2 Results Expected

Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1• Influenza1,162

Apr 16Estimated

CT.gov

00%

days

REGNPhase 2$113.8B

Carboplatin Phase 2 Results Expected

Carboplatin• Resectable Non-small Cell Lung Cancer195

Apr 17Estimated

CT.gov

00%

LSTAPhase 2$24M

certepetide Phase 2 Results Expected

certepetide• Cholangiocarcinoma67

Apr 18Estimated

CT.gov

00%

MRKPhase 2$245.9B

ATRA Phase 2 Results Expected

ATRA• Melanoma315

Apr 20Estimated

CT.gov

00%

MRKPhase 2$245.9B

Vibostolimab Phase 2 Results Expected

Vibostolimab• Melanoma315

Apr 20Estimated

CT.gov

00%

MRKPhase 2$245.9B

Pembrolizumab/Quavonlimab Phase 2 Results Expected

Pembrolizumab/Quavonlimab• Colorectal Cancer315

Apr 20Estimated

CT.gov

00%

MRKPhase 2$245.9B

lenvatinib Phase 2 Results Expected

Lenvatinib• Non-small Cell Lung Cancer315

Apr 20Estimated

CT.gov

00%

MRKPhase 2$245.9B

pembrolizumab Phase 2 Results Expected

pembrolizumab• Non-small Cell Lung Cancer315

Apr 20Estimated

CT.gov

00%

MRKPhase 2$245.9B

Zilovertamab vedotin Phase 2 Results Expected

MK-2140 (zilovertamab vedotin)• Relapsed or Refractory Diffuse Large B-Cell Lymphoma140

Apr 22Estimated

CT.gov

00%

RHHBYPhase 2$328.4B

RO7795081 Phase 2 Results Expected

RO7795081• Obesity or Overweight340

Apr 23Estimated

CT.gov

00%

HNSPFPhase 2$31.2B

HS-10374 Phase 2 Results Expected

HS-10374• Psoriatic Arthritis160

Apr 28Estimated

CT.gov

00%

VRNAPhase 2$1.1B

Ensifentrine 3 mg Phase 2 Results Expected

Ensifentrine 3 mg• Chronic Obstructive Pulmonary Disease480

Apr 29Estimated

CT.gov

00%

VRNAPhase 2$1.1B

Glycopyrrolate 21.25 mcg Phase 2 Results Expected

Glycopyrrolate 21.25 mcg• Chronic Obstructive Pulmonary Disease480

Apr 29Estimated

CT.gov

00%

TLSAPhase 2$146M

Foralumab TZLS-401 100 µg Phase 2 Results Expected

Foralumab TZLS-401 100 µg• Non-Active Secondary Progressive Multiple Sclerosis55

Apr 30Estimated

CT.gov

00%

PFEPhase 2$142.7B

Samuraciclib Phase 2 Results Expected

Samuraciclib• Breast Cancer11

Apr 30Estimated

CT.gov

00%

PFEPhase 2$142.7B

vepdegestrant Phase 2 Results Expected

vepdegestrant• Breast Cancer11

Apr 30Estimated

CT.gov

00%

TTIPFPhase 2$20M

TTI-0102 Phase 2 Results Expected

TTI-0102• MELAS Syndrome12

Apr 30Estimated

CT.gov

00%

MRKPhase 2$245.9B

Tulisokibart Phase 2 Results Expected

Tulisokibart• Hidradenitis Suppurativa154

Apr 30Estimated

CT.gov

00%

VRTXPhase 2$121.8B

Placebo (matched to pregabalin) Phase 2 Results Expected

VX-548• Acute Pain300

Apr 30Estimated

CT.gov

00%

CNTAPhase 2$3.7B

ORX750 Phase 2 Results Expected

ORX750• Narcolepsy Type 190

Apr 30Estimated

CT.gov

00%

GSKPhase 2$118.7B

Zanamivir Phase 2 Results Expected

Zanamivir• Influenza, Human12

Apr 30Estimated

CT.gov

00%

DNLIPhase 2$1.9B

BIIB122 225 mg Phase 2 Results Expected

BIIB122 225 mg• Parkinson Disease50

Apr 30Estimated

CT.gov

00%

AZNCFPhase 2$290.6B

Tozorakimab Phase 2 Results Expected

Tozorakimab• Asthma98

Apr 30Estimated

CT.gov

00%

ANROPhase 2$590M

DR30206 Phase 2 Results Expected

DR30206• Gastrointestinal Cancer186

Apr 30Estimated

CT.gov

00%

May 202651

BAVA.COPhase 2$15.6B

MVA-BN Phase 2 Results Expected

MVA-BN• Monkeypox (Mpox)460

May 1Estimated

CT.gov

00%

AZNCFPhase 2$290.6B

AZD7798 Phase 2 Results Expected

AZD7798• Moderate to Severe Crohn's Disease120

May 1Estimated

CT.gov

00%

CELZPhase 2$5M

CELZ-201-DDT Phase 2 Results Expected

CELZ-201-DDT• Chronic Low-back Pain45

May 1Estimated

CT.gov

00%

AZNPhase 2$314.2B

AZD7798 Phase 2 Results Expected

AZD7798• Crohn's Disease30

May 4Estimated

CT.gov

00%

RCKTPhase 2$1.4B

RP-L102 Phase 2 Results Expected

RP-L102• Fanconi Anemia Complementation Group A5

May 5Estimated

CT.gov

00%

INCYPhase 2$9.9B

INCB177054 Phase 2 Results Expected

INCB177054• Solid Tumors9

May 8Estimated

CT.gov

00%

AZNPhase 2$314.2B

AZD3470 Phase 2 Results Expected

AZD3470• Lymphoma110

May 8Estimated

CT.gov

00%

CLCSPhase 2$26K

mesenchymal stem cells Phase 2 Results Expected

mesenchymal stem cells• Lung Injury80

May 10Estimated

CT.gov

00%

NVSPhase 2$274.7B

CPK850 Phase 2 Results Expected

CPK850• Retinitis Pigmentosa12

May 11Estimated

CT.gov

00%

ALPMYPhase 2$28.9B

enfortumab vedotin (EV) Phase 2 Results Expected

enfortumab vedotin (EV)• Carcinoma, Transitional Cell348

May 11Estimated

CT.gov

00%

HCMPhase 2$2.6B

HMPL-760 planned dose 1 Phase 2 Results Expected

HMPL-760 planned dose 1• Relapsed/Refractory Diffuse Large B-Cell Lymphoma61

May 12Estimated

CT.gov

00%

REGNPhase 2$113.8B

Cemiplimab Phase 2 Results Expected

cemiplimab• Advanced Cutaneous Squamous Cell Carcinoma180

May 13Estimated

CT.gov

00%

REGNPhase 2$113.8B

Pemetrexed Phase 2 Results Expected

Pemetrexed• Non-small Cell Lung Cancer180

May 13Estimated

CT.gov

00%

REGNPhase 2$113.8B

Fianlimab Phase 2 Results Expected

Fianlimab• Melanoma180

May 13Estimated

CT.gov

00%

REGNPhase 2$113.8B

Placebo Phase 2 Results Expected

Dupilumab• Atopic Dermatitis (AD)180

May 13Estimated

CT.gov

00%

BIIBPhase 2$33.7B

BIIB080 Phase 2 Results Expected

BIIB080• Alzheimer Disease416

BTDFTOrphan

May 14Estimated

CT.gov

00%

RHHBYPhase 2$328.4B

Entrectinib Phase 2 Results Expected

Entrectinib• Solid Tumors534

May 14Estimated

CT.gov

00%

2mo

GNFT.PAPhase 2$416M

GNS561 + Trametinib Phase 2 Results Expected

GNS561 + Trametinib• Cholangiocarcinoma74

May 15Estimated

CT.gov

00%

2mo

TNGXPhase 2$855M

TNG462 Phase 2 Results Expected

TNG462• Locally Advanced Solid Tumor225

May 15Estimated

CT.gov

00%

2mo

GILDPhase 2$60.0B

Sacituzumab Govitecan-hziy Phase 2 Results Expected

Sacituzumab Govitecan-hziy• Triple Negative Breast Cancer135

May 15Estimated

CT.gov

00%

2mo

ARWRPhase 2$1.4B

ARO-INHBE Phase 2 Results Expected

ARO-INHBE• Obesity120

May 15Estimated

CT.gov

00%

2mo

CODXPhase 2$10M

Test Product HY07121 Phase 2 Results Expected

Test Product HY07121• Safety258

May 15Estimated

CT.gov

00%

2mo

SBFMPhase 2$7M

Clifutinib Besylate Phase 2 Results Expected

Clifutinib Besylate• Acute Myeloid Leukemia, Adult133

May 15Estimated

CT.gov

00%

2mo

EVMNPhase 2$892M

EVO756 Phase 2 Results Expected

EVO756• Chronic Spontaneous Urticaria160

May 15Estimated

CT.gov

00%

2mo

GLUEPhase 2$1.3B

Oral MRT-2359 Phase 2 Results Expected

Oral MRT-2359• NSCLC174

May 15Estimated

CT.gov

00%

2mo

WSTPhase 2$19.4B

RVU120 (SEL120) Phase 2 Results Expected

RVU120 (SEL120)• Low Risk Myelodysplastic Syndromes41

May 15Estimated

CT.gov

00%

2mo

GILDPhase 2$60.0B

Emtricitabine/tenofovir disoproxil fumarate (F/TDF) Phase 2 Results Expected

Emtricitabine/tenofovir disoproxil fumarate (F/TDF)• Pre-Exposure Prophylaxis of HIV Infection268

May 15Estimated

CT.gov

00%

2mo

ENTXPhase 2$85M

EBP05 Phase 2 Results Expected

EBP05• Hypoparathyroidism45

May 15Estimated

CT.gov

00%

2mo

BLCOPhase 2$598M

BL1107 Low dose Phase 2 Results Expected

BL1107 Low dose• Glaucoma228

May 15Estimated

CT.gov

00%

2mo

LLYPhase 2$769.8B

Mevidalen Phase 2 Results Expected

Mevidalen• Alzheimer Disease300

May 15Estimated

CT.gov

00%

2mo

GILDPhase 2$60.0B

Lenacapavir Injection Phase 2 Results Expected

Lenacapavir Injection• Pre-Exposure Prophylaxis of HIV Infection268

May 15Estimated

CT.gov

00%

2mo

AGIOPhase 2$2.4B

Tebapivat Phase 2 Results Expected

Tebapivat• Myelodysplastic Syndromes56

May 15Estimated

CT.gov

00%

2mo

ALTPhase 2$469M

Pemvidutide Phase 2 Results Expected

Pemvidutide• Alcohol Use Disorder (AUD)100

May 15Estimated

CT.gov

00%

2mo

REGNPhase 2$113.8B

Trevogrumab-Part A Phase 2 Results Expected

Trevogrumab-Part A• Obesity1,005

May 18Estimated

CT.gov

00%

2mo

REGNPhase 2$113.8B

Garetosmab Phase 2 Results Expected

Garetosmab• Fibrodysplasia Ossificans Progressiva1,005

May 18Estimated

CT.gov

00%

2mo

MRKPhase 2$245.9B

coformulation pembrolizumab/quavonlimab Phase 2 Results Expected

coformulation pembrolizumab/quavonlimab• Small Cell Lung Carcinoma110

May 20Estimated

CT.gov

00%

2mo

PBMPhase 2$6M

Psilocybin therapy Phase 2 Results Expected

Psilocybin therapy• Adjustment Disorder87

May 21Estimated

CT.gov

00%

2mo

PFEPhase 2$142.7B

Multivalent Pneumococcal Vaccine - Formulation 1 Phase 2 Results Expected

Multivalent Pneumococcal Vaccine - Formulation 1• Pneumococcal Disease558

May 23Estimated

CT.gov

00%

2mo

AZNPhase 2$314.2B

AZD9550 Phase 2 Results Expected

AZD9550• Overweight and Obesity377

May 25Estimated

CT.gov

00%

2mo

AZNCFPhase 2$290.6B

AZD6234 Phase 2 Results Expected

AZD9550• Obesity or Overweight377

May 25Estimated

CT.gov

00%

2mo

AZNCFPhase 2$290.6B

AZD6234 Phase 2 Results Expected

AZD6234• Endocrinology69

May 27Estimated

CT.gov

00%

2mo

MRNAPhase 2$42.1B

mRNA-1345 Phase 2 Results Expected

mRNA-1345• Respiratory Syncytial Virus360

May 27Estimated

CT.gov

00%

2mo

SNYPhase 2$115.3B

Pandemic flu H5 HA mRNA SD2 vaccine Phase 2 Results Expected

Pandemic flu H5 HA mRNA SD2 vaccine• Pandemic Influenza Immunization

May 28Estimated

CT.gov

00%

2mo

VRTXPhase 2$121.8B

VX-264 Phase 2 Results Expected

VX-264• Type 1 Diabetes7

May 29Estimated

CT.gov

00%

2mo

DVAXPhase 2$800M

rF1V-1018 Phase 2 Results Expected

rF1V-1018• Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis148

May 29Estimated

CT.gov

00%

2mo

ANROPhase 2$590M

DR10624 Injection Phase 2 Results Expected

DR10624 Injection• MASLD110

May 30Estimated

CT.gov

00%

2mo

SVAPhase 2$642M

Low-dose experimental vaccine Phase 2 Results Expected

Low-dose experimental vaccine• Herpes Zoster519

May 31Estimated

CT.gov

00%

2mo

MRKPhase 2$245.9B

MK-4830 Phase 2 Results Expected

MK-4830• Carcinoma, Non-Small-Cell Lung370

May 31Estimated

CT.gov

00%

2mo

MRKPhase 2$245.9B

Vibostolimab/Pembrolizumab Phase 2 Results Expected

Vibostolimab/Pembrolizumab• Carcinoma, Renal Cell400

May 31Estimated

CT.gov

00%

2mo

MRKPhase 2$245.9B

Favezelimab/Pembrolizumab Phase 2 Results Expected

favezelimab/pembrolizumab• Hodgkin Lymphoma400

May 31Estimated

CT.gov

00%

2mo

CELG-RIPhase 2

BMS-986158 Phase 2 Results Expected

BMS-986158• Myelofibrosis216

May 31Estimated

CT.gov

00%

Get Phase 2 Clinical Trials Alerts

About Phase 2 Clinical Trials

Mid-stage Phase 2 clinical trial results showing efficacy and safety data.